Abstract: Metabolic associated fatty liver disease (MAFLD) has gradually become the most common liver disease in the world with the globalization of obesity, diabetes, and metabolic syndrome. It is reported that 50%-75% patients with diabetics have MAFLD. Since drugs are not available, the main management strategy for MAFLD is to adopt a healthy lifestyle, such as proper exercise and diet. In recent years, liraglutide has been found by more and more scholars that it can not only reduce blood glucose and lipid and improve insulin resistance, but also has many therapeutic effects, such as reducing liver fat accumulation, slowing down MASH, and significantly reducing the degree of liver fibrosis. In this article, we review and summarize the effects of liraglutide in the treatment of T2DM complicated with MAFLD and the latest research progress.

Key words: Liraglutide, Type 2 diabetes, Metabolic associated fatty liver disease

摘要： 随着肥胖、糖尿病及其代谢综合征的全球化，代谢相关脂肪性肝病（MAFLD）逐渐成为全球最普遍的肝脏疾病。据报道，50%～75%的糖尿病患者患有MAFLD。由于没有药物可用，目前通过调整健康的生活方式，如恰当的运动及合理的饮食习惯，仍然是MAFLD的主要管理策略。近几年，利拉鲁肽被越来越多的学者发现，它不仅可以降低血糖血脂、改善胰岛素抵抗，还拥有减少肝脏脂肪堆积，减缓代谢相关脂肪性肝炎（MASH）和显著降低肝纤维化程度等诸多疗效。在本篇综述文章中，我们回顾并总结了利拉鲁肽在治疗2型糖尿病（T2DM）合并MAFLD中的诸多作用和最新的研究进展。

关键词: 利拉鲁肽, 2型糖尿病, 代谢相关脂肪性肝病